Faller Packaging to buy Greek pharma packaging business Paperpack

Pharmaceutical packaging, the cartons, leaflets, and labeled containers that hold and identify medicines before they reach patients, is the business at the center of a new European deal. Faller Packaging has agreed to acquire Paperpack, a Greek company that works in the pharmaceutical and healthcare sectors. The two sides disclosed no financial terms.

The transaction extends Faller's presence across Europe. Paperpack operates primarily in Greece and South-Eastern Europe, a geographic footprint that sits alongside Faller's broader continental network. Both companies work in similar segments of the packaging market. Faller described the businesses as "highly complementary." Regulatory approval is still required before the deal can close.

What each side says it gains

Paperpack CEO Dimitris Tsiftsis said his company had built its reputation on quality, reliability, and customer relationships developed over many years. He described Faller as a partner with a wider product portfolio and an established European network. In his telling, the combination creates room to reach new customers, open new opportunities for Paperpack's employees, and accelerate the business's next phase of growth.

Tsiftsis also pointed to what he wants to preserve. He said Paperpack intends to keep building on the qualities that made it successful. The implication is that this is not a turnaround. It is an attempt to scale something that is already working.

Faller Packaging CEO Dagmar Schmidt described the purchase as another step in executing her company's growth strategy. She said the deal strengthens Faller's reach in South-Eastern Europe and expands the company's capacity to support pharmaceutical and healthcare customers across the region. She also framed the acquisition as a signal of Faller's long-term commitment to those two sectors.

What was signed versus what is still conditional

What exists on paper: a purchase agreement, contingent on regulatory clearance. What remains projection: every revenue gain, market expansion, and new customer opportunity that either executive described. No numbers were attached to those outcomes, and no timeline for regulatory sign-off was given.

The short version is that two European pharmaceutical packaging businesses have agreed to combine, with no disclosed price and no confirmed close date.